NCT06067425View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 10, 2023

Primary Completion Date

February 12, 2025

Study Completion Date

February 12, 2025

Conditions
Osteochondrodysplasia
Interventions
DRUG

SAR442501

Solution for injection; Subcutaneous injection

Trial Locations (9)

3052

Investigational Site Number : 0360001, Parkville

20122

Investigational Site Number : 3800002, Milan

200120

Investigational Site Number : 1560002, Shanghai

430030

Investigational Site Number : 1560001, Wuhan

00168

Investigational Site Number : 3800001, Rome

03080

Investigational Site Number : 4100001, Seoul

06351

Investigational Site Number : 4100002, Seoul

01008

Investigational Site Number : 7240002, Vitoria-Gasteiz

08950

Investigational Site Number : 7240001, Esplugues de Llobregat

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT06067425 - Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia | Biotech Hunter | Biotech Hunter